Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non–Small Cell Lung Cancer

[1]  A. Akabane,et al.  A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. , 2017, International journal of radiation oncology, biology, physics.

[2]  J. Buckner,et al.  Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[3]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[4]  S. Gettinger,et al.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Socinski,et al.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Brown,et al.  The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.

[7]  N. Yeh,et al.  Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Volker W Stieber,et al.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.

[9]  Satoshi Suzuki,et al.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. , 2014, The Lancet. Oncology.

[10]  Dong-Yeop Shin,et al.  EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  L. Trodella,et al.  Fractionated stereotactic radiosurgery for patients with brain metastases , 2014, Journal of Neuro-Oncology.

[12]  A. Bozzao,et al.  Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis , 2011, Radiation oncology.

[13]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[14]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[15]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[16]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[18]  P. Jänne,et al.  MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials , 2017 .